Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.63 |
| ▸ | PKM | P14618 | 2/20 | 0.63 |
| ▸ | MAPT | P10636 | 7/20 | 0.62 |
| ▸ | RAB9A | P51151 | 4/20 | 0.62 |
| ▸ | NPC1 | O15118 | 4/20 | 0.62 |
| ▸ | KAT2B | Q92831 | 2/20 | 0.62 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.61 |
| ▸ | GAA | P10253 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | RECQL | P46063 | 1/20 | 0.59 |
| ▸ | POLB | P06746 | 1/20 | 0.57 |
| ▸ | HTR6 | P50406 | 2/20 | 0.56 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.53 |
| ▸ | HTT | P42858 | 1/20 | 0.53 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8150179 | 0.91 | MAPT (0.58) | KMT2APKMMAPTRAB9ANPC1 | |
| SCHEMBL19278391 | 0.88 | ALDH1A1 (0.56) | KMT2APKMMAPTRAB9ANPC1 | |
| SCHEMBL6198859 | 0.86 | KAT2B (0.80) | KMT2AMAPTRAB9ANPC1KAT2B | |
| SCHEMBL4936233 | 0.84 | MAPT (0.56) | KMT2APKMMAPTRAB9ANPC1 | |
| SCHEMBL3400808 | 0.84 | SMN1; SMN2 (0.70) | KMT2APKMMAPTRAB9ANPC1 | |
| SCHEMBL102602 | 0.83 | MAPT (0.77) | KMT2AMAPTRAB9ANPC1KAT2B | |
| SCHEMBL1470938 | 0.83 | KAT2B (0.61) | KMT2AMAPTRAB9ANPC1KAT2B | |
| SCHEMBL6200169 | 0.82 | KAT2B (0.81) | KMT2AMAPTRAB9ANPC1KAT2B | |
| SCHEMBL7170020 | 0.82 | KAT2B (0.81) | KMT2AMAPTRAB9ANPC1KAT2B | |
| SCHEMBL10581784 | 0.82 | HTR6 (0.59) | KMT2APKMMAPTRAB9ANPC1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 30 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104651476-B | Novel nitroreductase substrates | 生物梅里埃公司 | 2020-02-18 | — | — | CN | disclosed |
| EP-2479282-B1 | Media including nitroreductase enzymatic substrates | BIOMERIEUX SA (FR) | 2018-03-28 | — | — | EP | disclosed |
| CN-104531832-B | Novel nitroreductase enzymatic substrates | 生物梅里埃公司 | 2017-10-27 | — | — | CN | disclosed |
| EP-2155893-B1 | NOVEL NITROREDUCTASE ENZYMATIC SUBSTRATES | BIOMERIEUX SA (FR) | 2016-10-19 | — | — | EP | disclosed |
| EP-2471944-B1 | Novel peptidase substrates | BIOMERIEUX SA (FR) | 2016-09-14 | — | — | EP | disclosed |
| EP-2155892-B1 | NOVEL PEPTIDASE SUBSTRATES | BIOMERIEUX SA (FR) | 2015-03-18 | — | — | EP | disclosed |
| US-8883826-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-11-11 | — | — | US | disclosed |
| US-8674106-B2 | Alkynyl derivatives as modulators of metabotropic glutamate receptors | ADDEX PHARMA SA (CH) | 2014-03-18 | — | — | US | disclosed |
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2013-07-11 | — | — | US | disclosed |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMA SA (CH) | 2012-11-01 | — | — | US | disclosed |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2009-05-14 | — | — | US | disclosed |
| WO-2008152305-A2 | NOVEL NITROREDUCTASE ENZYMATIC SUBSTRATES | bioMérieux (FR) | 2008-12-18 | — | — | WO | disclosed |
| WO-2008152306-A2 | NOVEL PEPTIDASE SUBSTRATES | bioMérieux (FR) | 2008-12-18 | — | — | WO | disclosed |
| EP-1765795-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | Addex Pharmaceuticals SA (CH) | 2007-03-28 | — | — | EP | disclosed |
| WO-2005123703-A2 | ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | ADDEX PHARMACEUTICALS SA (CH) | 2005-12-29 | — | — | WO | disclosed |
| US-6399629-B1 | PYRROLIDINES AND PIPERIDINES FOR TREATING MICROBIAL INFECTIONS BY REDUCING EXPORT OF COADMINISTERED ANTIMICROBIAL AGENT OR COMPOUND SYNTHESIZED BY MICROBES FOR THEIR GROWTH; REDUCING IN VIVO AVAILABILITY | MICROCIDE PHARMACEUTICALS, INC. | 2002-06-04 | — | — | US | disclosed |
| WO-2000001714-A1 | EFFLUX PUMP INHIBITORS | MICROCIDE PHARMACEUTICALS, INC. (US) | 2000-01-13 | — | — | WO | disclosed |
| US-5075304-A | Nervous system disorders | NOVO NORDISK A/S (DK) | 1991-12-24 | — | — | US | disclosed |
| EP-0344943-A1 | Imidazoquinoxaline compounds and their preparation and use | NOVO NORDISK A/S (DK) | 1989-12-06 | — | — | EP | disclosed |
| EP-0009800-B1 | 4-PHENYL-1,3-BENZODIAZEPINES, METHOD FOR THEIR PREPARATION, PHARMACEUTICAL COMPOSITIONS CONTAINING THEM, AND THE COMPOUNDS FOR USE AS MEDICAMENTS | HOECHST AKTIENGESELLSCHAFT (DE) | 1983-02-23 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130178631-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | KMT2A 2181/4885PKM 2176/4885MAPT 1113/4885 |
| US-20090124625-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METATROPIC GLUTAMATE RECEPTORS | GRM5, GRM2, GRM1 | KMT2A 1833/4885PKM 2122/4885MAPT 630/4885 |
| US-20120277237-A1 | NOVEL ALKYNYL DERIVATIVES AS MODULATORS OF METABOTROPIC GLUTAMATE RECEPTORS | GRM5, GRM1, GRM2 | KMT2A 2181/4885PKM 2176/4885MAPT 1113/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.